Skip to main content

Market Overview

Why AstraZeneca Stock Is Trading Higher Today


AstraZeneca (NASDAQ: AZN) shares are trading higher after the company announced lynparza PROpel trial met the primary endpoint in metastatic castration-resistant prostate cancer.

"We are encouraged by the PROpel results and the clinical benefit LYNPARZAin combination with abiraterone demonstrated versus abiraterone alone as a 1st-line treatment option for men with metastatic castration-resistant prostate cancer. Today's results build on Merck (NYSE: MRK) and AstraZeneca's commitment to bring LYNPARZA earlier in lines of treatmentand to more patients with advanced prostate cancer," said Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, Merck.

The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. 

AstraZeneca has a 52-week high of $60.93 and a 52-week low of $46.48.


Related Articles (AZN)

View Comments and Join the Discussion!

Posted-In: Roy Barnes why it's movingNews

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at